Today's Business Headlines: 10/22/24
Thousands of bottles of a commonly prescribed antidepressant drug have been recalled by the FDA because they were found to contain a suspected cancer-causing chemical.
EY fires dozens of staffers for taking multiple online trainings at a time — but employees say company 'encouraged' this “There are multiple reasons why nitrosamines can be present in drugs. FDA found the source of nitrosamines can be related to the drug’s manufacturing process or its chemical structure or even the conditions in which they are stored or packaged,” the FDA said in a statement according to the outlet. “As foods and drugs are processed in the body, nitrosamines can also be formed. FDA continues to test and research possible sources for drugs found to contain nitrosamines.
The FDA “recommends patients talk to their health care professional about the best course of action for their health if they have a medication that has been recalled,” the administrationImmediately stopping duloxetine can cause withdrawal side effects with short-term effects appearing in as little as a few hours and lasting for up to 6 weeks,Tapering off antidepressant use depends on how long a patient has been taking the drug, with health officials recommending a four-week period of dose...
Anxiety Depression Fda Prescription Drugs Recalls
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Thousands of duloxetine bottles, an antidepressant sold as Cymbalta, recalled over toxic chemicalSome bottles of the antidepressant duloxetine, sold under the brand name Cymbalta, were recalled due to the presence of a toxic chemical.
Read more »
FDA Approves New Treatment for Advanced Parkinson’s DiseaseThe FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
Read more »
FDA Approves Revolutionary Schizophrenia DrugIn a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name Cobenfy, targets a different pathway in the brain, offering new hope for treatment.
Read more »
Bimbo Bakeries Defies FDA Warning Over Sesame LabelingDespite an FDA warning that several Bimbo Bakeries USA products are misbranded due to sesame labeling, the company insists on maintaining its current labels, claiming it protects sesame-allergic consumers.
Read more »
FDA approves 1st new drug to treat schizophrenia in more than 30 yearsThe FDA on Thursday approved the first new drug to treat patients with schizophrenia in more than 30 years.
Read more »
FDA Approves Potentially Groundbreaking Schizophrenia DrugOn Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades.
Read more »